Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Clinical Study to Assess the Safety and Efficacy of CN128 Tablets in the Treatment of Iron Overload in Transfusion Dependent Thalassemia Patients Aged 16 and Above

NCT04614779 is registered in ClinicalTrials.gov with Hangzhou Zede Pharma-Tech Co., Ltd. as lead sponsor.

NCT NCT04614779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04614779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Clinical Study to Assess the Safety and Efficacy of CN128 Tablets in the Treatment of Iron Overload in Transfusion Dependent Thalassemia Patients Aged 16 and Above
Lead sponsor
Hangzhou Zede Pharma-Tech Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2020
Completion date
August 18, 2022
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

iron overload, thalassemia